Quality of Life Impact of an Adjuvanted Recombinant Zoster Vaccine in Adults Aged 50 Years and Older

Overview

Journal J Gerontol A Biol Sci Med Sci

Specialty Geriatrics

Date 2018 Jun 30

PMID 29955836

Citations 27

Authors

Desmond Curran

Lidia Oostvogels

Thomas Heineman

Sean Matthews

Janet McElhaney

Shelly McNeil

Javier Diez-Domingo

Himal Lal

Charles Andrews

Eugene Athan

Johan Berglund

Laura Campora

Ferdinandus De Looze

Tiina Korhonen

Edward Leung

Myron Levin

Antonio Volpi

Robert W Johnson

Affiliations

Soon will be listed here.

Abstract

Background: To determine the efficacy of an adjuvanted recombinant zoster vaccine in reducing the herpes zoster (HZ) burden of illness, HZ burden of interference with activities of daily living, and HZ impact on quality of life.

Methods: The assessments were integrated in two Phase III trials, ZOE-50 (NCT01165177) and ZOE-70 (NCT01165229). HZ burden of illness and HZ burden of interference with activities of daily living were assessed by the Zoster Brief Pain Inventory (ZBPI) instrument and quality of life by the EuroQol-5 Dimension (EQ-5D) utility index and the SF-36 health survey. We report the ZOE-50 results and a pooled analysis of patients aged 70 years and older from the trials combined.

Results: The estimated vaccine efficacy in reducing HZ burden of illness and HZ burden of interference was greater than 90% in both the ZOE-50 and the pooled ZOE-70 analysis. In confirmed HZ cases, adjuvanted recombinant zoster vaccine reduced the maximal ZBPI worst-pain score in the pooled ZOE-70 analysis (p = .032) and the maximal ZBPI average-pain scores in both the ZOE-50 (p = .049) and the pooled ZOE-70 analysis (p = .043). In breakthrough HZ cases, trends for diminished loss of quality of life compared with placebo-recipient HZ cases were observed, with differences up to 0.14 on the EQ-5D index at time points during the 4 weeks following HZ onset.

Conclusions: Adjuvanted recombinant zoster vaccine reduced the HZ burden of illness significantly, particularly due to its very high vaccine efficacy in preventing HZ. For breakthrough HZ cases, the results suggest that the adjuvanted recombinant zoster vaccine mitigated severity of HZ-related pain, burden of interference with activities of daily living, and recipients' utility loss.

Citing Articles

Public health impact of herpes zoster vaccination on older adults in Singapore: a modeling study.

Oh H, Tan C, Williams C, Giannelos N, Ng C Hum Vaccin Immunother. 2024; 20(1):2348839.

PMID: 38804600 PMC: 11135959. DOI: 10.1080/21645515.2024.2348839.

The respiratory syncytial virus prefusion F protein vaccine attenuates the severity of respiratory syncytial virus-associated disease in breakthrough infections in adults ≥60 years of age.

Curran D, Matthews S, Cabrera E, Perez S, Breva L, Ramet M Influenza Other Respir Viruses. 2024; 18(2):e13236.

PMID: 38314063 PMC: 10837780. DOI: 10.1111/irv.13236.

Healthy ageing: Herpes zoster infection and the role of zoster vaccination.

Curran D, Doherty T, Lecrenier N, Breuer T NPJ Vaccines. 2023; 8(1):184.

PMID: 38017011 PMC: 10684688. DOI: 10.1038/s41541-023-00757-0.

Recombinant zoster vaccine in immunocompetent and immunocompromised adults: A review of clinical studies.

Mwakingwe-Omari A, Lecrenier N, Naficy A, Curran D, Posiuniene I Hum Vaccin Immunother. 2023; 19(3):2278362.

PMID: 37965770 PMC: 10653762. DOI: 10.1080/21645515.2023.2278362.

Efficacy and safety of the recombinant zoster vaccine: A systematic review and meta-analysis.

Zeevaert R, Thiry N, Maertens de Noordhout C, Roberfroid D Vaccine X. 2023; 15:100397.

PMID: 37867572 PMC: 10589374. DOI: 10.1016/j.jvacx.2023.100397.

References

Rabin R, de Charro F . EQ-5D: a measure of health status from the EuroQol Group. Ann Med. 2001; 33(5):337-43. DOI: 10.3109/07853890109002087. View

Gershon A, Gershon M . Pathogenesis and current approaches to control of varicella-zoster virus infections. Clin Microbiol Rev. 2013; 26(4):728-43. PMC: 3811230. DOI: 10.1128/CMR.00052-13. View

Gater A, Abetz-Webb L, Carroll S, Mannan A, Serpell M, Johnson R . Burden of herpes zoster in the UK: findings from the zoster quality of life (ZQOL) study. BMC Infect Dis. 2014; 14:402. PMC: 4223600. DOI: 10.1186/1471-2334-14-402. View

Vesikari T, Giaquinto C, Huppertz H . Clinical trials of rotavirus vaccines in Europe. Pediatr Infect Dis J. 2006; 25(1 Suppl):S42-7. DOI: 10.1097/01.inf.0000197565.45345.4e. View

Oxman M, Levin M, Johnson G, Schmader K, Straus S, Gelb L . A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. N Engl J Med. 2005; 352(22):2271-84. DOI: 10.1056/NEJMoa051016. View

Coplan P, Schmader K, Nikas A, Chan I, Choo P, Levin M . Development of a measure of the burden of pain due to herpes zoster and postherpetic neuralgia for prevention trials: adaptation of the brief pain inventory. J Pain. 2004; 5(6):344-56. DOI: 10.1016/j.jpain.2004.06.001. View

Moore L, Remy V, Martin M, Beillat M, McGuire A . A health economic model for evaluating a vaccine for the prevention of herpes zoster and post-herpetic neuralgia in the UK. Cost Eff Resour Alloc. 2010; 8:7. PMC: 2881001. DOI: 10.1186/1478-7547-8-7. View

Kawai K, Preaud E, Baron-Papillon F, Largeron N, Acosta C . Cost-effectiveness of vaccination against herpes zoster and postherpetic neuralgia: a critical review. Vaccine. 2014; 32(15):1645-53. DOI: 10.1016/j.vaccine.2014.01.058. View

Lukas K, Edte A, Bertrand I . The impact of herpes zoster and post-herpetic neuralgia on quality of life: patient-reported outcomes in six European countries. Z Gesundh Wiss. 2012; 20(4):441-451. PMC: 3397124. DOI: 10.1007/s10389-011-0481-8. View

10.

Cunningham A, Lal H, Kovac M, Chlibek R, Hwang S, Diez-Domingo J . Efficacy of the Herpes Zoster Subunit Vaccine in Adults 70 Years of Age or Older. N Engl J Med. 2016; 375(11):1019-32. DOI: 10.1056/NEJMoa1603800. View

11.

Oster G, Harding G, Dukes E, Edelsberg J, Cleary P . Pain, medication use, and health-related quality of life in older persons with postherpetic neuralgia: results from a population-based survey. J Pain. 2005; 6(6):356-63. DOI: 10.1016/j.jpain.2005.01.359. View

12.

Lal H, Cunningham A, Godeaux O, Chlibek R, Diez-Domingo J, Hwang S . Efficacy of an adjuvanted herpes zoster subunit vaccine in older adults. N Engl J Med. 2015; 372(22):2087-96. DOI: 10.1056/NEJMoa1501184. View

13.

Ware Jr J . SF-36 health survey update. Spine (Phila Pa 1976). 2000; 25(24):3130-9. DOI: 10.1097/00007632-200012150-00008. View

14.

Farrington C, Manning G . Test statistics and sample size formulae for comparative binomial trials with null hypothesis of non-zero risk difference or non-unity relative risk. Stat Med. 1990; 9(12):1447-54. DOI: 10.1002/sim.4780091208. View

15.

Johnson R, Bouhassira D, Kassianos G, Leplege A, Schmader K, Weinke T . The impact of herpes zoster and post-herpetic neuralgia on quality-of-life. BMC Med. 2010; 8:37. PMC: 2905321. DOI: 10.1186/1741-7015-8-37. View

16.

Ehrlich H, Singer J, Berezuk G, Fritsch S, Aichinger G, Hart M . A cell culture-derived influenza vaccine provides consistent protection against infection and reduces the duration and severity of disease in infected individuals. Clin Infect Dis. 2012; 54(7):946-54. PMC: 3297649. DOI: 10.1093/cid/cir959. View

17.

Katz J, Cooper E, Walther R, Sweeney E, Dworkin R . Acute pain in herpes zoster and its impact on health-related quality of life. Clin Infect Dis. 2004; 39(3):342-8. DOI: 10.1086/421942. View

18.

Follmann D, Fay M, Proschan M . Chop-lump tests for vaccine trials. Biometrics. 2009; 65(3):885-93. DOI: 10.1111/j.1541-0420.2008.01131.x. View

19.

Schmader K . Herpes zoster in older adults. Clin Infect Dis. 2001; 32(10):1481-6. DOI: 10.1086/320169. View

20.

Pellissier J, Brisson M, Levin M . Evaluation of the cost-effectiveness in the United States of a vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. Vaccine. 2007; 25(49):8326-37. DOI: 10.1016/j.vaccine.2007.09.066. View